MX2021006003A - Formulaciones de anticuerpos cristalinos. - Google Patents

Formulaciones de anticuerpos cristalinos.

Info

Publication number
MX2021006003A
MX2021006003A MX2021006003A MX2021006003A MX2021006003A MX 2021006003 A MX2021006003 A MX 2021006003A MX 2021006003 A MX2021006003 A MX 2021006003A MX 2021006003 A MX2021006003 A MX 2021006003A MX 2021006003 A MX2021006003 A MX 2021006003A
Authority
MX
Mexico
Prior art keywords
antibody formulations
crystalline antibody
crystalline
formulations
antibody crystals
Prior art date
Application number
MX2021006003A
Other languages
English (en)
Inventor
Christi L Clogston
Twinkle R Christian
Timothy David Osslund
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2021006003A publication Critical patent/MX2021006003A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente cristales de anticuerpo anti-PCSK9, métodos para elaborar tales cristales de anticuerpo y formulaciones que comprenden los cristales de anticuerpo.
MX2021006003A 2014-07-14 2017-01-12 Formulaciones de anticuerpos cristalinos. MX2021006003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462024399P 2014-07-14 2014-07-14

Publications (1)

Publication Number Publication Date
MX2021006003A true MX2021006003A (es) 2021-07-06

Family

ID=53716611

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017000526A MX2017000526A (es) 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos.
MX2021006003A MX2021006003A (es) 2014-07-14 2017-01-12 Formulaciones de anticuerpos cristalinos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017000526A MX2017000526A (es) 2014-07-14 2015-07-13 Formulaciones de anticuerpos cristalinos.

Country Status (7)

Country Link
US (2) US10611850B2 (es)
EP (2) EP3169709B1 (es)
JP (4) JP6783223B2 (es)
AU (2) AU2015289967A1 (es)
CA (1) CA2954773C (es)
MX (2) MX2017000526A (es)
WO (1) WO2016010924A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957898B (zh) 2011-11-18 2016-02-24 瑞泽恩制药公司 聚合物蛋白微粒
WO2016010927A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
MX2017000526A (es) * 2014-07-14 2017-08-02 Amgen Inc Formulaciones de anticuerpos cristalinos.
CA3001346A1 (en) * 2015-10-16 2017-04-20 Regeneron Pharmaceuticals, Inc. Stable protein compositions
WO2019099427A1 (en) * 2017-11-14 2019-05-23 The University Of North Carolina At Chapel Hill Compositions and methods for stabilization of proteins
GB2584687B (en) * 2019-06-11 2023-08-23 Univ Newcastle Crystallisation of chemical molecules

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10503179A (ja) 1994-06-24 1998-03-24 イミュネックス・コーポレーション 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法
IL112834A (en) 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6432449B1 (en) 1998-05-18 2002-08-13 Amgen Inc. Biodegradable sustained-release alginate gels
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
WO2002072636A2 (en) * 2000-12-28 2002-09-19 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2016010927A1 (en) 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
MX2017000526A (es) * 2014-07-14 2017-08-02 Amgen Inc Formulaciones de anticuerpos cristalinos.

Also Published As

Publication number Publication date
EP3929218A1 (en) 2021-12-29
EP3169709A1 (en) 2017-05-24
JP2023055977A (ja) 2023-04-18
MX2017000526A (es) 2017-08-02
CA2954773C (en) 2023-10-03
JP2017525679A (ja) 2017-09-07
JP2018141004A (ja) 2018-09-13
US20170198058A1 (en) 2017-07-13
CA2954773A1 (en) 2016-01-21
JP6783223B2 (ja) 2020-11-11
AU2015289967A1 (en) 2017-02-02
EP3169709B1 (en) 2021-05-12
JP2020169200A (ja) 2020-10-15
US20200299410A1 (en) 2020-09-24
US10611850B2 (en) 2020-04-07
US11773184B2 (en) 2023-10-03
AU2021201409A1 (en) 2021-03-25
WO2016010924A1 (en) 2016-01-21
JP7264853B2 (ja) 2023-04-25

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
PH12016501763A1 (en) Multispecific antibodies
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MY176285A (en) Anti-fcrh5 antibodies
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
MX2017007941A (es) Anticuerpos antagonistas anti-axl.
MX2017006694A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX2020012893A (es) Formulaciones de proteinas.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MY167350A (en) Fat-and-oil composition and chocolate
MX2019010640A (es) Formas cristalinas de acido obeticolico.
NZ721832A (en) Solid forms of tenofovir
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
MX2015010789A (es) Anticuerpos anti-pcsm.
NZ744340A (en) Anti-jagged1 antibodies and methods of use